ライフサイエンスコーパス: saphenous vein

1 11 for RA vs. ITA, and p < 0.001 for ITA vs. saphenous vein).

2 (e.g., 733 +/- 44 U/g of tissue at 6 hrs in saphenous vein).

3 duced neointimal formation in cultured human saphenous vein.

4 m aortic and coronary artery, as well as the saphenous vein.

5 panel graft constructed of recipient greater saphenous vein.

6 to those of the internal mammary artery and saphenous vein.

7 hich all others are compared--is the greater saphenous vein.

8 g-term patency of this conduit compared with saphenous vein.

9 ater than that of internal mammary artery or saphenous vein.

10 e was obtained with smooth muscle cells from saphenous vein.

11 s of normal human aorta, mammary artery, and saphenous vein.

12 reoperation over single thoracic artery with saphenous vein.

13 smooth muscle cells were cultured from human saphenous vein.

14 for the saphenous vein (p = 0.002 for RA vs. saphenous vein, 0.11 for RA vs. ITA, and p < 0.001 for I

15 ammary artery (6.2+/-0.3 pmol/mg protein) or saphenous vein (1.4+/-0.2 pmol/mg protein, both P<0.05).

16 ammary artery (3.5+/-1.3 pmol/mg protein) or saphenous vein (1.4+/-0.3 pmol/mg protein, both P<0.0001

17 er than internal mammary artery (56+/-9%) or saphenous vein (11+/-5%, both P<0.0001).

18 89%; 95% confidence interval [CI], 86%-93%; saphenous vein, 239/269; 89%; 95% CI, 85%-93%; adjusted

19 %) than internal mammary artery (23+/-6%) or saphenous vein (5+/-2%, both P<0.05).

20 internal mammary artery (203+/-32 nmol/L) or saphenous vein (97+/-12 nmol/L, both P<0.05).

21 = 65 years) in mammary artery (no change in saphenous vein), accompanied by increased alpha(1b)>alph

22 that this axis behaves the same as the great saphenous vein after treatment.

23 that this axis behaves the same as the great saphenous vein after treatment.

24 reas internalization in large vessel EC from saphenous vein and aorta is rapid, like HUVEC.

25 Segments of saphenous vein and internal mammary artery and confluent

26 ynthase (eNOS) uncoupling were quantified in saphenous vein and internal mammary artery segments.

27 ivo release were quantified in perivascular (saphenous vein and internal mammary artery) subcutaneous

28 In smooth muscle cells cultured from saphenous vein and internal mammary artery, bacterial li

29 ent human smooth muscle cells, cultured from saphenous vein and internal mammary artery, were exposed

30 eceptors were shown to be expressed in human saphenous vein and internal mammary artery.

31 nd BH4 levels were determined in segments of saphenous vein and internal mammary artery.

32 imately 90% and 50% of cells in intact human saphenous vein and rat myocardium, respectively.

33 tylcholine and bradykinin were determined in saphenous veins and internal mammary arteries from 117 p

34 superoxide production was quantified in both saphenous veins and internal mammary arteries from 45 di

35 F, and total homocysteine were determined in saphenous veins and internal mammary arteries obtained d

36 Samples of saphenous veins and internal mammary arteries were colle

37 sma and vascular biopterins (P<0.05 for both saphenous veins and internal mammary arteries).

38 In ex vivo experiments with human saphenous veins and internal mammary arteries, adiponect

39 3.8+/-0.8% in the internal mammary arteries, saphenous veins, and normal coronary arteries, respectiv

40 istance arteries, internal mammary arteries, saphenous veins, and small subcutaneous veins were studi

41 d during stenting in 22 patients with severe saphenous vein aorto-coronary bypass stenoses.

42 he angiographic patency of radial artery and saphenous vein aortocoronary bypass grafts at 5 years af

43 bosis, which is the final common pathway for saphenous vein arterial bypass graft occlusion.

44 rimary, isolated CABG with the LITA, RA, and saphenous vein as needed.

45 been performed most often with the patient's saphenous vein as the conduit.

46 nous enhancement (99 HU) was observed in the saphenous vein at the ankle, with all other venous stati

47 henous veins before organ culture and in pig saphenous veins before interposition grafting into carot

48 essed TIMP-3 at the luminal surface of human saphenous veins before organ culture and in pig saphenou

49 Here, we use the saphenous vein bleeding model to compare the efficacy of

50 easured by thromboelastography and prolonged saphenous-vein bleeding times, which are consistent with

51 ments from either internal mammary artery or saphenous vein, both forskolin and 8-Br-cAMP inhibited l

52 f 100 sternotomy CABG patients using IMA and saphenous veins, both treating equivalent number of targ

53 cantly augmented BH4 levels in plasma and in saphenous vein (but not internal mammary artery) but als

54 The use of aortic connectors for proximal saphenous vein bypass graft anastomoses eliminates the n

55 ting in the treatment of native coronary and saphenous vein bypass graft disease.

56 ssel constriction in diseased human coronary saphenous vein bypass grafts (SVBGs).

57 utaneous revascularization (PCI) of diseased saphenous vein bypass grafts (SVGs).

58 At angiography, 20 saphenous vein bypass grafts containing 19 connectors we

59 on in recanalization of chronically occluded saphenous vein bypass grafts in a large sample of patien

60 External stenting of saphenous vein bypass grafts reduces early intimal and m

61 els and studies in patients (coronary artery saphenous vein bypass grafts, lesions of restenosis afte

62 me has been disappointing so far, except for saphenous vein bypass grafts.

63 and with graft stenosis and occlusion after saphenous vein bypass surgery.

64 ructive changes often occur in aortocoronary saphenous-vein bypass grafts because of atherosclerosis

65 (749 patients) were compared with those with saphenous-vein bypass grafts only (4888 patients) with r

66 tion in patients with in-stent restenosis of saphenous-vein bypass grafts.

67 In segments of intact saphenous vein, C-type natriuretic peptide was significa

68 We determined whether human saphenous veins can be transduced with adenovirus vector

69 ase as the quest for an alternative graft to saphenous vein continues.

70 Results from a functional assay (rabbit saphenous vein contraction) demonstrate that certain dim

71 nts who underwent angioplasty of an occluded saphenous vein coronary artery bypass graft between Augu

72 Autologous saphenous vein coronary artery bypass graft surgery is c

73 that may prevent early and late occlusion of saphenous vein coronary bypass conduits.

74 complications during stenting of degenerated saphenous vein coronary bypass grafts are reduced, but n

75 Degeneration of saphenous vein coronary bypass grafts has become a commo

76 nstable angina, peripheral arterial disease, saphenous vein coronary bypass grafts, and diabetic reti

77 As compared with saphenous-vein coronary bypass grafts, internal-thoracic

78 Reports of early success with cryopreserved saphenous veins (CSV) as arterial conduits led us to dev

79 ine the effects of MARCKS silencing in human saphenous vein cultured ex vivo.

80 Compare the reparative potential of saphenous vein-derived pericytes (SVPs) with that of car

81 MT1-MMP expression in human saphenous vein-derived smooth muscle cells (SMCs) mainta

82 Primary cultures of human saphenous vein endothelial cells (ECs) and vascular smoo

83 ere incubated with IFN-gamma-activated human saphenous vein endothelial cells (HSVEC), but not with r

84 in bovine aortic endothelial cells and human saphenous vein endothelial cells in vitro and in adult m

85 to human erythroleukemia cells and to human saphenous vein endothelial cells was mediated by both al

86 Human saphenous vein endothelial cells were treated with ox-LD

87 ls of the hH1 isoform are expressed in human saphenous vein endothelium and that the presence of thes

88 In saphenous vein endothelium exposed to arterial flow cond

89 tion suppressed vascular remodeling of human saphenous vein explants ex vivo.

90 s for portal interposition and cryopreserved saphenous veins for arterial interposition in liver tran

91 Limitations in the long-term patency of saphenous veins for bypass grafts have encouraged intere

92 Segments of internal mammary artery and saphenous vein from patients undergoing coronary artery

93 ve resulted in more favorable outcomes after saphenous vein graft (SVG) angioplasty.

94 stent implantation versus stenting alone for saphenous vein graft (SVG) aortoostial lesions.

95 The pattern of saphenous vein graft (SVG) calcification before percutan

96 aft on long-term outcomes after percutaneous saphenous vein graft (SVG) intervention is currently unk

97 t of creatine kinase (CK-MB) elevation after saphenous vein graft (SVG) intervention is high, its pro

98 use of embolic protection devices (EPD) for saphenous vein graft (SVG) intervention; however, studie

99 We sought to examine saphenous vein graft (SVG) lesions that fail within the

100 sealing intermediate nonobstructive coronary saphenous vein graft (SVG) lesions with drug-eluting ste

101 PES) and a similar bare-metal stent (BMS) in saphenous vein graft (SVG) lesions.

102 et effect of aspirin, or both, contribute to saphenous vein graft (SVG) occlusion after coronary arte

103 pose of this study was to present radial and saphenous vein graft (SVG) occlusion results more than 5

104 assess disease progression in nonintervened saphenous vein graft (SVG) segments to determine the nat

105 Treatment of saphenous vein graft (SVG) stenosis with percutaneous co

106 63.3%) were lower for patients who underwent saphenous vein graft (SVG) stenting than for those with

107 ectiveness of gamma-irradiation ((192)Ir) in saphenous vein graft (SVG) versus native coronary artery

108 cutaneous coronary intervention (PCI) of the saphenous vein graft (SVG).

109 20%) also received an RA graft instead of a saphenous vein graft (SVG).

110 25 women) underwent stenting of 212 vessels (saphenous vein graft [53%], left anterior descending cor

111 ) or conventional treatment (n = 395) in the Saphenous Vein Graft Angioplasty Free of Emboli Randomiz

112 Saphenous vein graft angioplasty has been limited by hig

113 ient and SVG characteristics associated with saphenous vein graft atherosclerosis progression.

114 Angiographic changes in saphenous vein graft conduits 4.3 years after entry were

115 lower FitzGibbon A patency for arterial and saphenous vein graft conduits and less effective revascu

116 ressure balloon inflations, stents placed in saphenous vein graft conduits, and stents placed with hi

117 bolysis in 39%, cardiogenic shock in 17% and saphenous vein graft culprit in 11% of patients.

118 e use of a radial artery graft compared with saphenous vein graft did not result in greater 1-year pa

119 sis, bifurcation lesions, left main disease, saphenous vein graft disease, and acute coronary syndrom

120 ve coronary arteries, inhibit the process of saphenous vein graft disease, and improve vein graft pat

121 Aortocoronary saphenous vein graft disease, with its increasing clinic

122 tionship may also be seen after treatment of saphenous vein graft disease.

123 feration of the intima is an early lesion of saphenous vein graft disease.

124 Late saphenous vein graft failure results from intimal and me

125 High success was achieved in the saphenous vein graft group.

126 The Protection During Saphenous Vein Graft Intervention to Prevent Distal Embo

127 When saphenous vein graft interventions were excluded, howeve

128 During saphenous vein graft interventions, particulate retrieve

129 essels, long coronary stenoses, and possibly saphenous vein graft interventions.

130 omes of embolic protection devices (EPDs) in saphenous vein graft interventions.

131 ative coronary artery stenoses (CAVEAT-I) or saphenous vein graft lesions (CAVEAT-II) were randomized

132 undergoing percutaneous intervention of 682 saphenous vein graft lesions were prospectively randomiz

133 ocation (78.6% in left main lesion, 69.7% in saphenous vein graft lesions, 42.4% in circumflex lesion

134 We recently demonstrated in a pig saphenous vein graft model that application of an extern

135 In patients undergoing DCA or PTCA of saphenous vein graft narrowings, the relationship betwee

136 h platelet activation (deep vein thrombosis; saphenous vein graft occlusion after coronary bypass sur

137 In contrast, saphenous vein graft patency declined over time and simi

138 Trials that aspirin (325 mg daily) improves saphenous vein graft patency early (7 to 10 days) and at

139 eft internal mammary artery), reperfusion B (saphenous vein graft perfusion).

140 Saphenous vein graft stenosis is a significant clinical

141 uardWire balloon or a vascular filter during saphenous vein graft stenting.

142 epeat revascularization than did multivessel saphenous vein graft stenting.

143 otection filter devices during uncomplicated saphenous vein graft, carotid, renal, and superficial fe

144 ere administered into the coronary artery or saphenous vein graft.

145 hen the infarct-related vessel is a diseased saphenous vein graft.

146 of retrograde CTO PCI via patent or occluded saphenous vein graft.

147 nt vessel was randomized to radial artery vs saphenous vein graft.

148 e center to have either the radial artery or saphenous vein grafted to a stenosed branch of the nativ

149 of patients undergoing a nonstaged multiple saphenous vein grafting (SVG) intervention with stents a

150 rteries (38.5%) and greater than that in new saphenous vein grafts (11.8%).

151 at the feasibility and safety of CTO PCI via saphenous vein grafts (19% of post-CABG cases) versus co

152 ternal mammary arteries (90.3%, P<0.0001) or saphenous vein grafts (64.0%, P=0.0016).

153 l conduits (85.8% versus 91.4%; P=0.003) and saphenous vein grafts (72.7% versus 80.4%; P<0.001).

154 ernal thoracic artery (LITA) supplemented by saphenous vein grafts (LITA+SVG) has been demonstrated i

155 EPDs were used in 21.2% of saphenous vein grafts (median age, 75; 23% women) and we

156 enosis rate of 15.1%, compared with 5.9% for saphenous vein grafts (P=0.0003) and 4.8% for left inter

157 atent radial artery grafts and 23% of patent saphenous vein grafts (P=0.01).

158 ception of patients treated with degenerated saphenous vein grafts (risk with placebo 16.3% vs. risk

159 This study defined long-term patency of saphenous vein grafts (SVG) and internal mammary artery

160 l outcome after percutaneous intervention of saphenous vein grafts (SVG) and to identify the predicto

161 iabetic patients after stent implantation in saphenous vein grafts (SVG).

162 S) for percutaneous coronary intervention in saphenous vein grafts (SVG).

163 Stenosis of saphenous vein grafts (SVGs) after coronary artery bypas

164 tomy prior to stent implantation in diseased saphenous vein grafts (SVGs) and thrombus-containing nat

165 Saphenous vein grafts (SVGs) are effective in relieving

166 Intimal hyperplasia of saphenous vein grafts (SVGs) can lead to subsequent graf

167 Because saphenous vein grafts (SVGs) exhibit greater cellular he

168 Percutaneous coronary intervention (PCI) of saphenous vein grafts (SVGs) has historically been assoc

169 In each patient, all saphenous vein grafts (SVGs) placed (n = 11) with the de

170 Aortocoronary saphenous vein grafts (SVGs) undergo structural changes

171 s related to successful stenting of diseased saphenous vein grafts (SVGs) using a novel filter-based

172 ercutaneous coronary interventions (PCIs) in saphenous vein grafts (SVGs) with thrombus have a high f

173 coronary interventions (PCIs) in degenerated saphenous vein grafts (SVGs) without distal embolic prot

174 before CABG would improve the redox state in saphenous vein grafts (SVGs), independently of low-densi

175 ruptured atherosclerotic plaques detected in saphenous vein grafts (SVGs).

176 ffects, is expressed in "arterialized" human saphenous vein grafts (SVGs).

177 of a high risk cohort treated with stents in saphenous vein grafts (SVGs).

178 gnificantly better than the patency rate for saphenous vein grafts and comparable to reported patency

179 findings were similar in native arteries and saphenous vein grafts and in lesions treated with one or

180 er superior long-term survival compared with saphenous vein grafts and should be considered in patien

181 erosclerotic progression among patients with saphenous vein grafts and that aggressive lipid lowering

182 nct to percutaneous intervention of diseased saphenous vein grafts and, compared with distal protecti

183 Saphenous vein grafts are exposed to hemodynamic stress

184 To achieve high success rate, use of saphenous vein grafts as retrograde conduits seems to be

185 nary stenting of stenoses in old (> 9 years) saphenous vein grafts can be successfully performed, wit

186 term studies have documented poor patency of saphenous vein grafts compared with internal thoracic ar

187 rafts are thought to be better conduits than saphenous vein grafts for coronary artery bypass graftin

188 The PercuSurge GuardWire was used in 17 saphenous vein grafts in 16 patients.

189 istal pore size 100 microns) were used in 47 saphenous vein grafts in 44 patients.

190 after percutaneous intervention in diseased saphenous vein grafts is reduced by distal microcirculat

191 placebo on progression of atherosclerosis in saphenous vein grafts of patients who had had CABG surge

192 placebo on progression of atherosclerosis in saphenous vein grafts of patients who had had CABG surge

193 Interventions were performed on either saphenous vein grafts or native vessels and utilized ang

194 enever possible during treatment of diseased saphenous vein grafts produced outcomes similar to those

195 Implantation of saphenous vein grafts promotes upregulation of NADPH oxi

196 Saphenous vein grafts remain patent for approximately 10

197 rates of drug-eluting stents, which outlive saphenous vein grafts to non-left anterior descending ve

198 Medical) was developed to rapidly anastomose saphenous vein grafts to the aorta during coronary bypas

199 Saphenous vein grafts used in coronary artery bypass gra

200 ; 98.3% of radial artery grafts and 86.4% of saphenous vein grafts were patent (P=0.04).

201 l of 594 patients undergoing stenting of 639 saphenous vein grafts were prospectively randomized, usi

202 Early and late patency of saphenous vein grafts were similar in patients with and

203 year clinical outcomes of patients receiving saphenous vein grafts with multiple (m-SVG) versus singl

204 ger vessels, in the right coronary artery or saphenous vein grafts, and for unfavorable lesion charac

205 xus and Cardiac Surgery) score, treatment of saphenous vein grafts, ostial lesions, and in-stent rest

206 anterior descending, right coronary artery, saphenous vein grafts, ostial lesions, or in-stent reste

207 rates than left internal mammary artery and saphenous vein grafts.

208 reased the progression of atherosclerosis in saphenous vein grafts.

209 in-stent restenosis in native coronaries and saphenous vein grafts.

210 ors for a rapid atherosclerotic attrition of saphenous vein grafts.

211 the detrimental effect of atherosclerosis on saphenous vein grafts.

212 n may reduce the risk of early thrombosis in saphenous vein grafts.

213 osclerotic plaques in native arteries and in saphenous vein grafts.

214 rnal thoracic artery (ITA) grafts and 20,066 saphenous vein grafts.

215 ncy has been shown to be superior to that of saphenous vein grafts.

216 , or ostial; total occlusions; bifurcations; saphenous vein grafts; and multivessel interventions) fr

217 Treatment of stenosis in saphenous-vein grafts after coronary-artery bypass surge

218 eight years in the curve for the group with saphenous-vein grafts only than in that for the group wi

219 of 120 patients with in-stent restenosis in saphenous-vein grafts, the majority of whom had diffuse

220 omes in patients with obstructive disease of saphenous-vein grafts.

221 up reported significantly more pain than the saphenous vein group 3 months after surgery; however, si

222 (366 in the radial artery group, 367 in the saphenous vein group).

223 operative baseline between radial artery and saphenous vein groups after adjusting for covariates (P

224 utive patients with primary unilateral great saphenous vein (GSV) reflux undergoing endovenous treatm

225 e consequences of radial artery harvest with saphenous vein harvest in patients undergoing elective c

226 al sternal wound infection, infection at the saphenous vein harvest site, stroke, renal failure, adul

227 hundred forty-two patients with sternal and saphenous vein harvest wounds had half of each wound clo

228 factor (VWF) by immunofluorescence in great saphenous veins harvested at cardiac bypass surgery.

229 Use of endoscopic saphenous vein harvesting has developed into a routine s

230 The human saphenous vein has a greater propensity for intimal hype

231 -C protein was not detected in control human saphenous veins; however, it was uniformly and strongly

232 Standard harvest and preparation of human saphenous vein (HSV) for autologous coronary and periphe

233 ue with a cumulative manner in ex vivo human saphenous vein (HSV) model.

234 n macrovascular endothelial cells from human saphenous vein (HSVEC).

235 ion of endothelial cells cultured from human saphenous vein (HSVECs) has identified a voltage-gated N

236 function in normal and atherosclerotic human saphenous vein imply a role for the peptide in the progr

237 Using human saphenous vein in a validated ex vivo flow circuit, we i

238 ides superior long-term patency rates to the saphenous vein in most situations.

239 reduced the average time to hemostasis after saphenous vein incision, and the time to occlusion after

240 ure base, centered on the treatment of great saphenous vein incompetence cannot simply be extrapolate

241 ents, smooth muscle cells were cultured from saphenous veins, incubated with our without bacterial li

242 the time to occlusion after FeCl(3)-induced saphenous vein injury.

243 was to assess thrombus age in patients with saphenous vein insufficiency treated with sclerotherapy.

244 l of intimal hyperplasia, we incubated human saphenous veins, internal mammary arteries, and radial a

245 In ex vivo experiments with human saphenous veins/internal mammary arteries and adipose ti

246 f stenotic coronary arteries with autologous saphenous vein is an established treatment for ischemic

247 number of arterial grafts into the LIMA plus saphenous veins (LIMA/SV) group (n=7435) or the MultArt

248 cation to the carotid artery (high shear) or saphenous vein (lower shear); hyperfibrinogenemia signif

249 Similar effects were observed in human saphenous vein medial segments where proliferation was r

250 F-positive MPs had increased thrombosis in a saphenous vein model.

251 mutation in FOXC2 showed reflux in the great saphenous vein (n=18), compared with only 1 of 12 refere

252 radial artery, internal mammary artery, and saphenous vein (n=24 patients) were examined by use of o

253 P)H oxidase activity was determined in human saphenous veins obtained from 110 patients with coronary

254 peroxide production were determined in human saphenous veins obtained from 133 patients with coronary

255 analysis had radial artery only (n = 80) or saphenous vein only (n = 337) harvest.

256 , and venous surgery not involving the great saphenous vein (OR = 15.61, P < 0.001).

257 - 0.2% for the RA, and 55.0 +/- 0.2% for the saphenous vein (p = 0.002 for RA vs. saphenous vein, 0.1

258 s of culture, the I/M ratio increased in the saphenous veins (P=0.03, P=0.04 versus 0 day, respective

259 atients enrolled in the Radial artery versus Saphenous Vein Patency (RSVP) trial.

260 recipients: 3 of 3 organ recipients, 1 of 2 saphenous vein recipients, 1 of 3 tendon recipients, and

261 Adenovirus-mediated gene transfer to human saphenous veins resulted in functional transgene express

262 M, provokes sustained contractures in rabbit saphenous vein rings with greater efficacy than noradren

263 ility was evaluated by organ bath studies on saphenous vein rings.

264 fibrinopeptides had no vasoactive effects on saphenous vein rings; however, fibrinogen (0-2 microM) a

265 rior descending artery, and radial artery or saphenous vein segments are used to graft the lateral an

266 l artery in vivo and by vasomotor studies in saphenous vein segments ex vivo.

267 nical significance was investigated by using saphenous vein segments from non-coronary heart disease

268 At operation, saphenous vein segments were explanted for VSMC culture.

269 growth factor-stimulated migration of human saphenous vein SMCs and decrease phosphorylation of the

270 tudy, transient transfection assays in human saphenous vein smooth muscle cells (HSVSMC) and pulmonar

271 od or from adult peripheral blood, and human saphenous vein smooth muscle cells (HSVSMCs) as a source

272 n was increased in carotid atherectomies and saphenous vein specimens from diabetic versus nondiabeti

273 trial comparing treatment options for small saphenous vein (SSV) incompetence exists, and there is n

274 trial comparing treatment options for small saphenous vein (SSV) incompetence exists, and there is n

275 diabetic and nonischemic patients undergoing saphenous vein stripping were used.

276 on is associated with intimal hyperplasia in saphenous vein (SV) bypass grafts.

277 operation: 2,389 had LITA grafting and 1,084 saphenous vein (SV) grafting to the LAD.

278 have significantly better patency rates than saphenous vein (SV) grafts at 5 years, but the physiolog

279 y artery, internal mammary artery (IMA), and saphenous vein (SV).

280 profiles of primary cultured ECs from human saphenous vein (SVEC) and coronary artery (CAEC) exposed

281 Internal mammary arteries (IMAs) and saphenous veins (SVs) were collected at the time of card

282 Exposure of VSMCs derived from human saphenous vein to C pneumoniae EBs (3x10(7) inclusion fo

283 ncRNAs whose expression was altered in human saphenous vein vascular smooth muscle cells following st

284 -derived growth factor-BB (PDGF-BB) in human saphenous vein VSMCs.

285 uccessful ablation of the main trunks of the saphenous vein was less common in the foam group than in

286 nsfers to inhibit intimal hyperplasia in the saphenous veins was evaluated.

287 Harvested segments of human saphenous vein were exposed for 1 hour at 37 degrees C t

288 Segments of internal mammary artery and saphenous vein were obtained during coronary artery bypa

289 ent, segments of internal mammary artery and saphenous vein were obtained during coronary artery bypa

290 nts, segments of internal mammary artery and saphenous vein were obtained from five patients who rece

291 Segments of internal mammary artery and saphenous vein were obtained from patients undergoing co

292 Segments of saphenous veins were incubated for 24 hrs in the presenc

293 reduced the adhesion of these cells to human saphenous vein, whereas PBM adhesion in the presence of

294 Adaptation of saphenous vein, with its intrinsic myogenic tone, from t